Disease-free Survival, Overall Survival
Conditions
Brief summary
Thermal ablation has been recommended by worldwide guidelines as first-line treatment for hepatocellular carcinoma (HCC), while evidence regarding its efficacy for primary intrahepatic cholangiocarcinoma (iCCA) is lacking. The goal of this observational study is to study the efficacy of ablation in treating iCCA by comparing its prognosis with surgery. The main questions it aims to answer are: * Whether microwave ablation could achieve similar efficacy with liver resection in treating iCCA * What is the risk factor for ablation or surgery in treating iCCA * What kind of iCCA patients could receive ablation as their first-line treatment In this real-world multicenter cohort study, we will collect data of iCCA patients from hospitals who underwent microwave ablation (MWA) or liver resection (LR) for tumors within Milan criteria. Survival will be compared between patients treated by MWA or LR.
Interventions
PROCEDUREMicrowave ablation (MWA) versus Liver Resection (LR)
Microwave ablation (MWA) is one of the newer modality of thermal ablation and has proven its safety and efficacy in the management of the tumors amenable for ablation for primary and metastatic diseases. Liver resection is a surgery to remove part of the liver to eradicate tumors.
Sponsors
Chinese PLA General Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. pathologically diagnosed iCCA based on the WHO classifications; 2. curative-intent liver resection or microwave ablation; 3. tumor within Milan criteria, namely single tumor ≤5cm in maximum diameter; multiple tumors ≤3 in number and each ≤3cm; no evidence of major vascular/hilar invasion, extrahepatic/lymphatic metastasis or other malignancies; 4. age ≥18 years.
Exclusion criteria
Patients not meeting any one of the inclusion criteria were excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | More than 3 years] | OS was defined as death related to any cause and was indexed from the date of ablation or surgery until last contact or death |
| Disease-free survival | More than 3 years | DFS was defined as the time interval between first treatment and recurrence or death, whichever occurred earlier. |
Countries
China
Contacts
Primary ContactChuan Pang, Doctor
Outcome results
None listed